{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T09:17:45Z","timestamp":1788254265852,"version":"build-2803163510"},"reference-count":20,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>We thank the authors for their interest in our analysis [...]<\/jats:p>","DOI":"10.3390\/vaccines14090759","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T08:31:13Z","timestamp":1788251473000},"page":"759","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Reply to Hodges et al. Comment on \u201cKura et al. Cost-Effectiveness Analysis of Clesrovimab for Respiratory Syncytial Virus in Infants in the United States. Vaccines 2026, 14, 411\u201d"],"prefix":"10.3390","volume":"14","author":[{"given":"Klodeta","family":"Kura","sequence":"first","affiliation":[{"name":"Health Economic and Decision Sciences, MSD (UK) Limited, London EC2M 6UR, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1770-2995","authenticated-orcid":false,"given":"John C.","family":"Lang","sequence":"additional","affiliation":[{"name":"Health Economic and Decision Sciences, Merck Canada Inc., Kirkland, QC H9H 4M7, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawei","family":"Wang","sequence":"additional","affiliation":[{"name":"Health Economic and Decision Sciences, Merck & Co., Inc., Rahway, NJ 07065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoonyoung","family":"Choi","sequence":"additional","affiliation":[{"name":"Epidemiology, Merck & Co., Inc., Rahway, NJ 07065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle G.","family":"Goveia","sequence":"additional","affiliation":[{"name":"Global Medical and Scientific Affairs, Merck & Co., Inc., Rahway, NJ 07065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anushua","family":"Sinha","sequence":"additional","affiliation":[{"name":"Global Clinical Development, Merck & Co., Inc., Rahway, NJ 07065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao-Hsuan","family":"Chen","sequence":"additional","affiliation":[{"name":"Health Economic and Decision Sciences, MSD (UK) Limited, London EC2M 6UR, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9993-8036","authenticated-orcid":false,"given":"Elamin H.","family":"Elbasha","sequence":"additional","affiliation":[{"name":"Health Economic and Decision Sciences, Merck & Co., Inc., Rahway, NJ 07065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Hodges, E.N., Ghemmouri, M., Neary, M.P., Gabriel, V., Ottaviano, C., Mari, K., Ottobrino, V., Chit, A., Domachowske, J., and Yarnoff, B. (2026). Comment on Kura et al. Cost-Effectiveness Analysis of Clesrovimab for Respiratory Syncytial Virus in Infants in the United States. Vaccines 2026, 14, 411. Vaccines, 14.","DOI":"10.3390\/vaccines14050411"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0197-2456(98)00042-7","article-title":"Sensitivity, specificity, and vaccine efficacy","volume":"19","author":"Lachenbruch","year":"1998","journal-title":"Control. Clin. Trials"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1056\/NEJMoa2502984","article-title":"Clesrovimab for Prevention of RSV Disease in Healthy Infants","volume":"393","author":"Zar","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S2352-4642(22)00321-2","article-title":"Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: A pooled analysis of randomised controlled trials","volume":"7","author":"Madhi","year":"2023","journal-title":"Lancet Child Adolesc. Health"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1056\/NEJMoa2110275","article-title":"Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants","volume":"386","author":"Hammitt","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2216480","article-title":"Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants","volume":"388","author":"Kampmann","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Shen, J., Kharitonova, E., Tytula, A., Zawieja, J., Aballea, S., Biswal, S., Sharma, M., Rungmaitree, S., Sruamsiri, R., and Wallace, D. (2025). Vaccination strategies, public health impact and cost-effectiveness of dengue vaccine TAK-003: A modeling case study in Thailand. PLoS Med., 22.","DOI":"10.1371\/journal.pmed.1004789"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1080\/13696998.2026.2624967","article-title":"Modeling the cost-effectiveness of the next-generation COVID-19 mRNA-1283 vaccine in the United States","volume":"29","author":"Fust","year":"2026","journal-title":"J. Med. Econ."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s41669-023-00438-7","article-title":"Cost-Effectiveness of Recombinant Zoster Vaccine for the Prevention of Herpes Zoster in Hematopoietic Stem Cell Transplant Recipients and Other Immunocompromised Adults in the United States","volume":"7","author":"Salem","year":"2023","journal-title":"PharmacoEcon. Open"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1183\/13993003.00325-2015","article-title":"Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands","volume":"46","author":"Mangen","year":"2015","journal-title":"Eur. Respir. J."},{"key":"ref_11","unstructured":"Moulia, D. (2025, January 16). Evidence to Recommendations Framework: Clesrovimab. [Presentation Slides]. Proceedings of the Advisory Committee on Immunization Practices Meeting, Atlanta, GA, USA. Available online: https:\/\/www.cdc.gov\/acip\/downloads\/slides-2025-04-15-16\/02-Moulia-maternal-peds-RSV-508.pdf."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Kura, K., Lang, J.C., Wang, D., Choi, Y., Goveia, M.G., Sinha, A., Chen, Y.-H., and Elbasha, E.H. (2026). Cost-Effectiveness Analysis of Clesrovimab for Respiratory Syncytial Virus in Infants in the United States. Vaccines, 14.","DOI":"10.3390\/vaccines14050411"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1007\/s40121-026-01311-w","article-title":"Cost-Effectiveness of Nirsevimab and Clesrovimab in Preventing Respiratory Syncytial Virus Lower Respiratory Tract Disease in Infants in the United States: A Modeling Study","volume":"15","author":"Yarnoff","year":"2026","journal-title":"Infect. Dis. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1080\/14760584.2025.2591816","article-title":"Comparison of the public health impact of RSV disease prevention options for infants: A static decision model of the US birth cohort","volume":"24","author":"Kieffer","year":"2025","journal-title":"Expert Rev. Vaccines"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Zar, H., Sim\u00f5es, E., Madhi, S., Ramilo, O., Senders, S., Shepard, J., Laoprasopwattana, K., Piedrahita, J., Novoa Pizarro, J., and Vargas, S. (2024, January 16\u201319). A Phase 2b\/3 Study to Evaluate the Efficacy and Safety of an Investigational Respiratory Syncytial Virus (RSV) Antibody, Clesrovimab, in Healthy Preterm and Full-Term Infants. Proceedings of the IDWeek 2024, Los Angeles, CA, USA.","DOI":"10.1093\/ofid\/ofae631.003"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1056\/NEJMc2214773","article-title":"Nirsevimab for Prevention of RSV in Term and Late-Preterm Infants","volume":"388","author":"Muller","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"920","DOI":"10.15585\/mmwr.mm7234a4","article-title":"Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2023","volume":"72","author":"Jones","year":"2023","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e2024066461","DOI":"10.1542\/peds.2024-066461","article-title":"Cost-Effectiveness of Nirsevimab for Respiratory Syncytial Virus in Infants and Young Children","volume":"154","author":"Hutton","year":"2024","journal-title":"Pediatrics"},{"key":"ref_19","unstructured":"Abdirizak, F., and Haynes, A. RSV Surveillance Data: 2010\u20132019, National Respiratory and Enteric Virus Surveillance System (NREVSS). Personal communication."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e2023062574","DOI":"10.1542\/peds.2023-062574","article-title":"Respiratory Syncytial Virus-Associated Hospitalizations Among Children <5 Years Old: 2016 to 2020","volume":"153","author":"Curns","year":"2024","journal-title":"Pediatrics"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/9\/759\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T08:44:24Z","timestamp":1788252264000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/9\/759"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":20,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["vaccines14090759"],"URL":"https:\/\/doi.org\/10.3390\/vaccines14090759","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]}}}